Ibrutinib (PCI-32765) is an orally available inhibitor of the BTK and has been approved for the treatment of several different types of hematological malignancies, such as chronic lymphocytic leukemia, mantle cell lymphoma, or Waldenström’s macroglobulinemia34. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.